Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing

European Journal of Clinical Pharmacology
Samuel FantaEija Kalso

Abstract

Low-dose ketamine is a lucrative therapeutic approach in cancer pain, perioperative treatment of pain, and management of treatment-resistant depression. The analgesic potency of its main metabolite norketamine is thought to be one third that of ketamine. However, few studies exist on the pharmacokinetics of orally administered S-ketamine. In our study, 11 healthy volunteers received S-ketamine 0.25 mg/kg orally and 0.125 mg/kg intravenously. S-ketamine and norketamine concentrations were measured up to 23.5 h post-dose. A population pharmacokinetic model was built to describe S-ketamine and norketamine pharmacokinetics. A three-compartment model for both S-ketamine and norketamine best described the data. To accommodate for the extensive formation of norketamine after oral S-ketamine, a separate presystemic absorption-phase component was included in addition to its systemic formation. The oral bioavailability of S-ketamine was low, 8% (11% interindividual variability), and its clearance was high, 95 L/h/70 kg (13% interindividual variability). Simulations suggested that after oral dosing, norketamine AUC at steady state is 16.5 times higher than that of S-ketamine. Given that the analgesic effect of S-ketamine is due to both S-...Continue Reading

References

Feb 1, 1975·Anesthesiology·P F WhiteC R Pudwill
Dec 1, 1992·Anesthesiology·E D Kharasch, R Labroo
Feb 1, 1985·British Journal of Anaesthesia·P F WhiteA J Trevor
Feb 1, 1982·Anesthesiology·P F WhiteA J Trevor
May 1, 1982·Journal of Pharmaceutical Sciences·J A ClementsI S Grant
Aug 1, 1981·British Journal of Anaesthesia·I S GrantJ A Clements
Nov 1, 1996·British Journal of Anaesthesia·L Arendt-NielsenA M Zbinden
Nov 24, 2001·Clinical Pharmacology and Therapeutics·H IhmsenJ Schüttler
Jun 18, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Youssef Hijazi, Roselyne Boulieu
May 1, 1965·Clinical Pharmacology and Therapeutics·E F DOMINOG CORSSEN
Jul 24, 2004·Anesthesia and Analgesia·Kathirvel SubramaniamRichard A Steinbrook
Dec 25, 2004·Anesthesiology·Sabine Himmelseher, Marcel E Durieux
Jan 18, 2006·British Journal of Anaesthesia·M WhiteM Dzoljic
Jan 27, 2006·The Cochrane Database of Systematic Reviews·R F BellE Kalso
Jul 21, 2006·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·E Visser, S A Schug
Jul 8, 2008·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Nahum NesherAvi A Weinbroum
Sep 3, 2008·European Journal of Clinical Pharmacology·Roger K Verbeeck
Nov 3, 2009·European Journal of Pain : EJP·Maren I BlonkFrank J P M Huygen
Jul 20, 2010·European Journal of Pain : EJP·Albert DahanElise Sarton
Mar 2, 2011·Paediatric Anaesthesia·Katharine E J BrunetteSimone Schulein
Feb 7, 2012·CNS Drugs·Sanjay J MathewJames W Murrough
Jun 9, 2012·Basic & Clinical Pharmacology & Toxicology·Marko A PeltoniemiKlaus T Olkkola
Jun 19, 2012·Biological Psychiatry·Marije Aan Het RotSanjay J Mathew
Nov 16, 2012·The Cochrane Database of Systematic Reviews·Rae F BellEija A Kalso

❮ Previous
Next ❯

Citations

Mar 29, 2016·Acta Pharmacologica Sinica·Mei GaoHong Liu
Mar 31, 2016·Clinical Pharmacokinetics·Marko A PeltoniemiTeijo I Saari
Jun 12, 2018·Expert Opinion on Drug Metabolism & Toxicology·Jui-Tai ChenRuei-Ming Chen
Jun 28, 2018·Pharmacological Reviews·Panos ZanosTodd D Gould
Apr 21, 2018·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Samit GangulyErin G Schuetz
Dec 15, 2015·Journal of Clinical Psychopharmacology·Yena LeeRoger S McIntyre
Jul 10, 2019·Expert Review of Neurotherapeutics·Jennifer SwainsonMichael L Demas
Jan 29, 2020·Expert Review of Clinical Pharmacology·Yunpeng YangSteven P Cohen
Dec 1, 2019·BMC Psychiatry·Sanne Y Smith-ApeldoornRobert A Schoevers
Feb 1, 2020·Current Topics in Medicinal Chemistry·Domenico De BerardisLaura Orsolini
Oct 1, 2020·Anesthesiology·Jasper KampUNKNOWN Ketamine Pharmacokinetic Study Group
Feb 20, 2017·Forensic Sciences Research·Ricardo Jorge Dinis-Oliveira
May 3, 2020·Advanced Emergency Nursing Journal·Matthew H BilhimerAshley K Holmes
Aug 13, 2020·Therapeutic Advances in Drug Safety·Mohammed S SalahudeenGregory M Peterson
Apr 14, 2019·Wiener medizinische Wochenschrift·Wolfgang JakschMartin Aigner
Mar 27, 2020·Journal of Palliative Medicine·Jennifer D DulinPatrick J Coyne
Oct 17, 2017·Paediatric Anaesthesia·Robert B FlintRon A A Mathôt
Jul 9, 2020·Journal of Clinical Psychopharmacology·Leo R SilberbauerDietmar Winkler
Apr 30, 2019·Advanced Emergency Nursing Journal·Wesley D DavisKatie Hooper
Feb 13, 2021·European Journal of Clinical Pharmacology·M E OttoMichiel J van Esdonk
Nov 20, 2020·European Journal of Clinical Pharmacology·Paul GlueNatalie J Medlicott
May 18, 2021·Frontiers in Neuroscience·Ezio CarboniAntonello Novelli
Dec 2, 2017·Molecular Pharmaceutics·Markus KeiserStefan Oswald
Dec 7, 2021·BJPsych Open·Sanne Y Smith-ApeldoornRobert A Schoevers

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.